Depressive disorders are common sequelae of cancer and its treatment. Fortunately, most of them are transient and respond to information, adequate explanation and emotional support from those involved in patient care. This article concentrates on the less common but more severe depressive disorders which require pharmacological strategies in addition to psychosocial interventions. Guidelines are suggested for identifying depressive disorders and the importance of ruling out potentially reversible organic pathology which may be responsible for the mood disturbance is also emphasized. Estimates of the prevalence of depressive disorders among cancer patients are provided and practical advice is offered on the choice of antidepressant, dosage and side-effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.